AbbVie, Neurocrine’s fibroid drug hits PhIII targets
admin 14th March 2018 Uncategorised 0A second late-stage study assessing AbbVie and Neurocrine’s experimental drug elagolix in women with uterine fibroids has met its primary endpoint.
More: AbbVie, Neurocrine’s fibroid drug hits PhIII targets
Source: News